Neumora Therapeutics (NMRA) stock plunged 80% after disappointing results from a depression treatment study. The company will investigate further and share updates at an upcoming conference. CEO remains optimistic due to strong financial position.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing